Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Tegavivint, a Transducin Beta-like Protein 1 (TBL1) Inhibitor, With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma

NCT07144254 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT07144254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07144254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Tegavivint, a Transducin Beta-like Protein 1 (TBL1) Inhibitor, With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
Lead sponsor
Emory University
Phase
Phase 1
Overall status
Recruiting
Start date
January 22, 2026
Completion date
May 31, 2028
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

osteosarcoma in children, osteosarcoma recurrent, refractory osteosarcoma, relapsed osteosarcoma